Does the media refer more to JBIO or ARCT?

In the previous week, Jade Biosciences and Jade Biosciences both had 2 articles in the media. Arcturus Therapeutics' average media sentiment score of 1.27 beat Jade Biosciences' score of 0.93 indicating that Arcturus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcturus Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARCT or AMPH?

In the previous week, Amphastar Pharmaceuticals had 1 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 3 mentions for Amphastar Pharmaceuticals and 2 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 1.27 beat Amphastar Pharmaceuticals' score of -0.28 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amphastar Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SLDB or ARCT?

In the previous week, Solid Biosciences and Solid Biosciences both had 2 articles in the media. Arcturus Therapeutics' average media sentiment score of 1.27 beat Solid Biosciences' score of 0.99 indicating that Arcturus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcturus Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Arcturus Therapeutics (ARCT) Competitors

$6.88 +0.06 (+0.88%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$7.02 +0.15 (+2.11%)

As of 06/26/2026 07:53 PM Eastern

Compare

ARCT vs. TBPH, OLMA, JBIO, AMPH, and SLDB

Should you buy Arcturus Therapeutics stock or one of its competitors? MarketBeat compares Arcturus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arcturus Therapeutics include Theravance Biopharma (TBPH), Olema Pharmaceuticals (OLMA), Jade Biosciences (JBIO), Amphastar Pharmaceuticals (AMPH), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry.

How does Arcturus Therapeutics compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Theravance Biopharma has a net margin of 104.34% compared to Arcturus Therapeutics' net margin of -143.80%. Theravance Biopharma's return on equity of 18.84% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%

Theravance Biopharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.36, meaning that its stock price is 136% more volatile than the broader market.

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Theravance Biopharma. MarketBeat recorded 2 mentions for Arcturus Therapeutics and 1 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 1.87 beat Arcturus Therapeutics' score of 1.27 indicating that Theravance Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Theravance Biopharma	Very Positive
Arcturus Therapeutics	Positive

Theravance Biopharma has higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	8.46	$105.89M	$2.20	8.01
Arcturus Therapeutics	$82.03M	2.38	-$65.78M	-$2.81	N/A

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Theravance Biopharma currently has a consensus price target of $21.40, suggesting a potential upside of 21.38%. Arcturus Therapeutics has a consensus price target of $25.44, suggesting a potential upside of 269.83%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Arcturus Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Theravance Biopharma beats Arcturus Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Olema Pharmaceuticals?

Arcturus Therapeutics (NASDAQ:ARCT) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

Olema Pharmaceuticals has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -143.80%. Arcturus Therapeutics' return on equity of -36.55% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%
Olema Pharmaceuticals	N/A	-46.00%	-41.22%

Arcturus Therapeutics has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	2.38	-$65.78M	-$2.81	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A

Arcturus Therapeutics presently has a consensus price target of $25.44, suggesting a potential upside of 269.83%. Olema Pharmaceuticals has a consensus price target of $44.10, suggesting a potential upside of 287.18%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Arcturus Therapeutics had 1 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 2 mentions for Arcturus Therapeutics and 1 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.89 beat Arcturus Therapeutics' score of 1.27 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Arcturus Therapeutics	Positive
Olema Pharmaceuticals	Very Positive

Arcturus Therapeutics has a beta of 2.36, indicating that its share price is 136% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market.

Summary

Arcturus Therapeutics beats Olema Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Jade Biosciences has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -143.80%. Arcturus Therapeutics' return on equity of -36.55% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%

Arcturus Therapeutics has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A
Arcturus Therapeutics	$82.03M	2.38	-$65.78M	-$2.81	N/A

Jade Biosciences has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.36, suggesting that its share price is 136% more volatile than the broader market.

94.5% of Arcturus Therapeutics shares are owned by institutional investors. 23.1% of Jade Biosciences shares are owned by insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Jade Biosciences and Jade Biosciences both had 2 articles in the media. Arcturus Therapeutics' average media sentiment score of 1.27 beat Jade Biosciences' score of 0.93 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcturus Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jade Biosciences presently has a consensus target price of $47.13, suggesting a potential upside of 114.20%. Arcturus Therapeutics has a consensus target price of $25.44, suggesting a potential upside of 269.83%. Given Arcturus Therapeutics' higher probable upside, analysts plainly believe Arcturus Therapeutics is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Arcturus Therapeutics beats Jade Biosciences on 10 of the 15 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Amphastar Pharmaceuticals?

Arcturus Therapeutics (NASDAQ:ARCT) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Amphastar Pharmaceuticals has higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	2.38	-$65.78M	-$2.81	N/A
Amphastar Pharmaceuticals	$719.89M	1.33	$98.09M	$1.66	13.12

In the previous week, Amphastar Pharmaceuticals had 1 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 3 mentions for Amphastar Pharmaceuticals and 2 mentions for Arcturus Therapeutics. Arcturus Therapeutics' average media sentiment score of 1.27 beat Amphastar Pharmaceuticals' score of -0.28 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amphastar Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 17.8% of Arcturus Therapeutics shares are held by insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Arcturus Therapeutics has a beta of 2.36, indicating that its share price is 136% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

Arcturus Therapeutics currently has a consensus price target of $25.44, suggesting a potential upside of 269.83%. Amphastar Pharmaceuticals has a consensus price target of $24.00, suggesting a potential upside of 10.19%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcturus Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Arcturus Therapeutics' net margin of -143.80%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%

Summary

Amphastar Pharmaceuticals beats Arcturus Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Solid Biosciences has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -143.80%. Arcturus Therapeutics' return on equity of -36.55% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Solid Biosciences and Solid Biosciences both had 2 articles in the media. Arcturus Therapeutics' average media sentiment score of 1.27 beat Solid Biosciences' score of 0.99 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcturus Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solid Biosciences has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.36, suggesting that its stock price is 136% more volatile than the broader market.

Solid Biosciences presently has a consensus price target of $17.00, suggesting a potential upside of 82.99%. Arcturus Therapeutics has a consensus price target of $25.44, suggesting a potential upside of 269.83%. Given Arcturus Therapeutics' higher possible upside, analysts clearly believe Arcturus Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67

Arcturus Therapeutics has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Arcturus Therapeutics	$82.03M	2.38	-$65.78M	-$2.81	N/A

Summary

Arcturus Therapeutics beats Solid Biosciences on 9 of the 14 factors compared between the two stocks.

Get Arcturus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARCT vs. The Competition

Export

Metric	Arcturus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$193.85M	$3.55B	$6.70B	$12.22B
Dividend Yield	N/A	2.25%	2.67%	6.13%
P/E Ratio	-2.45	21.56	25.76	24.17
Price / Sales	2.38	334.67	559.68	101.60
Price / Cash	N/A	137.38	46.99	54.37
Price / Book	0.91	8.34	10.77	6.35
Net Income	-$65.78M	$23.91M	$3.57B	$337.63M
7 Day Performance	-8.63%	3.38%	2.15%	0.06%
1 Month Performance	-10.18%	1.51%	1.06%	-0.15%
1 Year Performance	-48.39%	65.14%	34.16%	27.55%

Arcturus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARCT Arcturus Therapeutics	2.7477 of 5 stars	$6.88 +0.9%	$25.44 +269.8%	-52.3%	$193.85M	$82.03M	N/A	180	News Coverage Positive News High Trading Volume
TBPH Theravance Biopharma	3.4557 of 5 stars	$16.56 -0.1%	$21.40 +29.2%	+64.3%	$854.75M	$109.78M	7.53	110	Positive News High Trading Volume
OLMA Olema Pharmaceuticals	2.8159 of 5 stars	$10.00 +5.2%	$44.10 +341.0%	+149.8%	$830.67M	N/A	N/A	70
JBIO Jade Biosciences	2.8785 of 5 stars	$19.45 +15.6%	$47.13 +142.3%	+137.8%	$830.23M	N/A	N/A	20
AMPH Amphastar Pharmaceuticals	2.6477 of 5 stars	$18.33 -2.6%	$24.00 +30.9%	-6.0%	$829.39M	$720.53M	11.04	1,976

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARCT) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcturus Therapeutics (ARCT) Competitors

ARCT vs. TBPH, OLMA, JBIO, AMPH, and SLDB

How does Arcturus Therapeutics compare to Theravance Biopharma?

Summary

How does Arcturus Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Arcturus Therapeutics compare to Jade Biosciences?

Summary

How does Arcturus Therapeutics compare to Amphastar Pharmaceuticals?

Summary

How does Arcturus Therapeutics compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT vs. The Competition

Arcturus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcturus Therapeutics (ARCT) Competitors

ARCT vs. TBPH, OLMA, JBIO, AMPH, and SLDB

How does Arcturus Therapeutics compare to Theravance Biopharma?

Is TBPH or ARCT more profitable?

Which has more volatility and risk, TBPH or ARCT?

Does the media prefer TBPH or ARCT?

Which has stronger valuation & earnings, TBPH or ARCT?

Do institutionals and insiders hold more shares of TBPH or ARCT?

Do analysts rate TBPH or ARCT?

Summary

How does Arcturus Therapeutics compare to Olema Pharmaceuticals?

Is ARCT or OLMA more profitable?

Which has preferable valuation & earnings, ARCT or OLMA?

Do analysts prefer ARCT or OLMA?

Do insiders & institutionals hold more shares of ARCT or OLMA?

Does the media prefer ARCT or OLMA?

Which has more risk & volatility, ARCT or OLMA?

Summary

How does Arcturus Therapeutics compare to Jade Biosciences?

Is JBIO or ARCT more profitable?

Which has preferable valuation & earnings, JBIO or ARCT?

Which has more risk and volatility, JBIO or ARCT?

Do institutionals & insiders believe in JBIO or ARCT?

Does the media refer more to JBIO or ARCT?

Do analysts rate JBIO or ARCT?

Summary

How does Arcturus Therapeutics compare to Amphastar Pharmaceuticals?

Which has preferable valuation and earnings, ARCT or AMPH?

Does the media favor ARCT or AMPH?

Do insiders and institutionals hold more shares of ARCT or AMPH?

Which has more volatility & risk, ARCT or AMPH?

Do analysts rate ARCT or AMPH?

Is ARCT or AMPH more profitable?

Summary

How does Arcturus Therapeutics compare to Solid Biosciences?

Is SLDB or ARCT more profitable?

Do institutionals and insiders hold more shares of SLDB or ARCT?

Does the media favor SLDB or ARCT?

Which has more volatility & risk, SLDB or ARCT?

Do analysts prefer SLDB or ARCT?

Which has preferable valuation & earnings, SLDB or ARCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT vs. The Competition

Arcturus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools